Browse Category

NASDAQ:KYMR.O News 2 January 2026

Kymera Therapeutics stock slides nearly 7% after CEO share-sale filing — what KYMR investors watch next

Kymera Therapeutics stock slides nearly 7% after CEO share-sale filing — what KYMR investors watch next

NEW YORK, Jan 2, 2026, 15:39 ET — Regular session Kymera Therapeutics Inc (KYMR.O) shares fell nearly 7% on Friday afternoon after a regulatory filing disclosed a year-end sale by Chief Executive Nello Mainolfi. Kymera was down 6.9% at $72.42, after earlier touching $72.18. The move matters because Kymera has become a high-sensitivity biotech name, with investor expectations tied closely…

Stock Market Today

  • AngloGold Ashanti's Strong Earnings Growth Draws Investor Interest
    January 31, 2026, 7:55 AM EST. AngloGold Ashanti (NYSE:AU) reported a striking rise in earnings per share (EPS), jumping from $1.34 to $4.46 in a year, signaling solid profit growth. The company's earnings before interest and tax (EBIT) margins expanded from 26% to 40%, alongside increasing revenues, indicating improved operational efficiency. With a market capitalization near $54 billion, insiders hold around $42 million in shares, reflecting significant personal investment. While past performance is promising, analysts caution investors to assess if this growth is sustainable or a one-time spike. AngloGold Ashanti's financial health and profitable metrics may appeal to investors seeking companies with consistent earnings rather than high-risk ventures.
Go toTop